In recent years, the adoption of high content screening in various phases of drug discovery has increased. The global was valued at $362.2 million in 2013 and is expected to reach $615.8 million by 2018, at a CAGR of 11.2%. The market is broadly classified based on products, applications, end users, and geographies.
The product market is further divided into instruments, consumables, software, and services. The instruments market is sub-divided into cell imaging and analysis systems and flow cytometers. The consumables market is further segmented into reagents and assay kits, microplates, and other consumables. The software market includes the market for image analysis and data management software. The services market includes screening services such as primary screening and secondary screening, services related to target identification and validation, toxicity studies, and compound profiling.
The applications market includes primary screening and secondary screening, target identification and validation, toxicity studies, compound profiling and other applications. High content screening can be applied in both primary and secondary screening, although it is extensively used for the secondary screening process. In target identification, HCS is used to identify novel targets through the screening of cellular pathways. HCS can also provide more accurate information related to drug toxicity and mode of actions that helps in further decision making and helps to drive the progress of drug discovery. The other application of HCS is in studying cell signaling pathways. The primary and secondary screening market dominated the high content screening applications market, with a market share of 50% in 2013.
The major factors driving the growth of the market include the need for determining the level of toxicity in the early stages of drug discovery pipeline, government support for cell-based research, and the introduction of enhanced informatics solutions and improved image analysis instruments. Moreover, the adoption of HCS for primary screening and its application in the development of personalized medicine are key growth opportunities in this market.
However, the high cost of the high content screening systems may hinder the growth of this market. In addition, the shortage of knowledgeable and skilled professionals for high content screening remains a major challenge for this market. The global market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). North America will continue to lead the global market in the forecast period, followed by Europe. Over the next five years, the growth of the global market in the Asian region is likely to be centered on China, Japan, Singapore, and India. This growth will be driven by government support for the growth of innovative technologies and the rising demand for outsourcing of drug discovery services.
Key Topics Covered
2 Executive Summary
3 Market Overview
4 Global High Content Screening Market, By Product Type 5 Global High Content Screening Market, By Application
6 Global High Content Screening End Users Market
7 Geographic Analysis
8 Competitive Landscape
9 Company Profiles
- Becton, Dickinson And Company
- Cell Signaling Technology
- Ge Healthcare (Subsidiary Of General Electric Company) - Genedata
- Thermo Fisher Scientific
- Yokogawa Electric
For more information visit http://www.researchandmarkets.com/research/ffpq8g/high_content
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Research and Markets,